<DOC>
	<DOCNO>NCT01273766</DOCNO>
	<brief_summary>RATIONALE : Deferasirox may remove excess iron body cause blood transfusion . PURPOSE : This clinical trial study deferasirox treat iron overload cause blood transfusion patient hematologic malignancy .</brief_summary>
	<brief_title>Deferasirox Treating Iron Overload Caused By Blood Transfusions Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine effect iron-chelating agent deferasirox change : neutrophil function ; macrophage function ; lymphocyte function . SECONDARY OBJECTIVES : I . To determine effect chelation incidence bacterial , viral fungal infection document clinical , microbiologically-proven versus radiologically-proven criterion . II . To determine effect iron chelation mortality morbidity incidence follow parameter : Need hospitalization ; Duration hospitalization ; Need ventilatory support ; Need exchange transfusion/apheresis ; Need treatment antifungal antibiotic document infection . OUTLINE : Patients receive oral deferasirox daily 6 month blood count recover absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients must pathology confirmed diagnosis one following : myelodysplastic syndrome ( MDS ) ; acute leukemia ; multiple myeloma ; myelofibrosis ; lymphoma ; chronic anemia ; sickle cell anemia Iron score &gt; = 2 Absolute Neutrophil Count ( ANC ) &gt; = 1,000 Platelets &gt; = 50,000 Albumin &gt; = 2 g/dL Alkaline phosphatase = &lt; 5X Upper Limit Normal ( ULN ) Total bilirubin = &lt; 1.5 Creatinine = &lt; 2X ageappropriate Upper Limit Normal ( ULN ) OR creatinine clearance &gt; = 40 ml/min Serum Glutamic Oxaloacetic Transaminase ( SGOT ) [ AST ] Serum Glutamic Pyruvic Transaminase ( SGPT ) [ ALT ] = &lt; 5X Upper Limit Normal ( ULN ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients active disease undergoing chemotherapy treatment Patient treat rituximab immunomodulating drug = &lt; 1 month prior enrollment HIVpositive patient HepatitisC positive patient Women pregnant breastfeeding Patients hemodialysis/patients renal failure Patients sepsis acute illness Known hypersensitivity deferasirox Patients moderate severe hearing loss define audiogram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>